PDCD1 and metastatic melanoma: Among TIMs, the frequency of a specific subset of monocytes, i.e., CD14+, CD16–, HLA-DRhigh monocytes, has been identified as predictor of progression-free and overall survival in patients with metastatic melanoma prior anti-PD-1 therapy (129).